Welcome to our dedicated page for Alcon SEC filings (Ticker: ALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alcon Inc. (ALC) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Alcon files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These filings include press releases, interim financial reports and other information that help investors understand the company’s operations in eye care and ophthalmic goods manufacturing.
Form 6-K submissions are a key source of timely information. Recent 6-Ks have furnished press releases about corporate actions and financial reporting, such as the November 12, 2025 filing that included a press release and an interim financial report, and the January 6, 2026 filing that attached a press release regarding the termination of Alcon’s merger agreement with STAAR Surgical Company. Another 6-K dated August 5, 2025 furnished a press release related to company developments.
Alcon’s filings also provide structured data on its business segments and financing. Segment disclosures in its interim financial reporting distinguish between the Surgical and Vision Care segments and further categorize areas such as implantables, consumables, equipment, contact lenses and ocular health. Other filing content details geographic reporting areas, debt instruments, and fair value measurements for financial assets and derivatives.
On this page, AI-powered tools can summarize lengthy Alcon filings, highlight key points from annual reports on Form 20-F and interim information furnished on Form 6-K, and help explain segment data and transaction disclosures. Users can review historical filings to track how Alcon reports on its Surgical and Vision Care businesses, capital structure and significant corporate events, including agreements and terminations related to mergers.
Form 144 notice filed relating to common stock through Fidelity Brokerage Services LLC. The filing lists planned transactions tied to restricted stock vesting dated
Alcon Inc. reports that 2025 was a transformative year, combining steady financial growth with a surge in innovation and social impact. Net sales reached $10.3 billion, up 5% as reported, or 4% on a constant currency basis. Diluted EPS was $1.98, with core diluted EPS of $3.07.
The company generated $2.3 billion in cash from operating activities and $1.7 billion in free cash flow, returning $848 million to shareholders via buybacks and dividends. Management highlights more than 10 significant product launches, including the Unity VCS surgical platform, PanOptix Pro intraocular lens, and TRYPTYR dry eye therapy, alongside strategic acquisitions such as LumiThera and Aurion Biotech.
Alcon emphasizes governance, board refreshment with the addition of Deborah Di Sanzo, and expanded social impact. In 2025 it completed 150,000 vision screenings for schoolchildren and improved or restored vision for over 5 million people with untreated cataracts, while setting new 2030 goals to broaden access and professional training.
Alcon Inc. filed its annual Form 20-F, providing a detailed overview of its global eye care business and risk profile for the year ended December 31, 2025. The company reports 487,427,920 ordinary shares outstanding as of the period end.
Alcon prepares consolidated financial statements in US dollars under IFRS as issued by the IASB and is listed on the NYSE and SIX Swiss Exchange. The report explains its focus on surgical ophthalmic devices, contact lenses and ocular health products, excluding spectacles and most prescription drugs.
The filing devotes extensive space to risk factors, highlighting cybersecurity and cloud-migration vulnerabilities, ethical and regulatory challenges from artificial intelligence, complex data privacy rules, and reliance on global supply chains and single-source suppliers. It also describes competitive pressures, heavy R&D needs, acquisition integration risks, exposure to China and other volatile markets, evolving healthcare reimbursement regimes, environmental and product-quality regulation, substantial goodwill and debt levels, and increasing complexity in global tax and sustainability requirements.
Alcon Inc. reported solid 2025 growth but softer margins and EPS as it invested behind new products and faced higher tariffs. Net sales reached $10.3 billion, up 5% year over year, with fourth‑quarter sales of $2.7 billion, up 9% on a reported basis and 7% in constant currency.
Full‑year operating income was $1.4 billion, down 4%, and diluted EPS slipped to $1.98 from $2.05, while core diluted EPS edged up to $3.07 from $3.05. The company generated $2.3 billion of operating cash flow and $1.7 billion of free cash flow, returning $848 million to shareholders via dividends and share repurchases, and completing a $750 million buyback program.
Alcon highlighted growth in Surgical consumables and equipment and in Vision Care, especially dry‑eye products and contact lenses, even as tariffs and higher R&D and marketing spend weighed on margins. For 2026, it targets constant‑currency net sales growth of 5%–7% and core diluted EPS growth of 9%–12%, supported by about $100 million of efficiency savings and continued new product launches.
Alcon and STAAR Surgical have agreed to an amended all-cash merger under which Alcon will acquire all outstanding STAAR shares for $30.75 per share, valuing the equity at about $1.6 billion.
The revised price adds roughly $150 million of equity value and represents a 74% premium to STAAR’s 90-day volume-weighted average price and a 66% premium to the August 4, 2025 closing price. Both boards have approved the deal, and STAAR’s board recommends that stockholders approve the transaction.
A prior “go-shop” process ended without a superior offer. Alcon plans to fund the purchase with short- and long-term credit facilities and expects the transaction to be accretive to earnings in year two, with closing anticipated in early 2026, subject to regulatory and STAAR stockholder approvals and other customary conditions.
Alcon filed investor materials supporting its proposed all-cash acquisition of STAAR Surgical at $28 per share, and plans outreach to STAAR stockholders. The materials emphasize offer context and comparisons, noting a 59% premium to the 90‑day VWAP of $18 and a 47% premium to the median sell-side price target of $19. Alcon also states it is the only interested buyer and encourages a board‑run 45‑day go‑shop without matching rights or a break‑up fee if a superior proposal emerges.
The communications reiterate that STAAR’s definitive proxy statement on Schedule 14A was filed and mailed on September 16, 2025, and include standard forward‑looking statements and risk factors, such as the need for stockholder approval and regulatory clearances. Alcon positions the transaction as aligned with sector precedents and at the high end of comparable ophthalmology deal multiples.